Regeneron Pharmaceuticals sees strength in Dupixent, oncology gains, and major buybacks despite setbacks. Find out why REGN ...

Biotech company Regeneron (NASDAQ:REGN) has seen its stock price rally by over 55% this year with the stock currently trading at about $600 per share, due to anticipation surrounding the company ...

Shares of Regeneron Pharmaceuticals, Inc. REGN have dropped 35.6% in the past six months compared with the industry’s decline of 12.3%. The stock has underperformed the sector and the S&P 500 ...

Regeneron (REGN) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended March 2025. This widely-known consensus outlook gives ...

Revenue declined 4% from the prior year, as Regeneron struggled to offset the double-digit decline in net product sales, including a 29% plunge in legacy EYLEA, despite a 54% jump in EYLEA HD ...

REGN stock fell 48.1% from a peak of $526.53 on 22 June 2017 to $273.46 on 27 September 2019, against a peak-to-trough decline of 33.9% for the S&P 500 The stock completely recovered to its pre ...

Regeneron Pharmaceuticals' (REGN) stock is trading in the red premarket on Thursday after net product sales ... COVID‑19 antibody therapy REGEN-COV saw a decline of -3.52% Y/Y to $613.2M in ...

Biotech company Regeneron (NASDAQ: REGN) has seen its stock price rally by over 55% this year with the stock currently trading at about $600 per share, due to anticipation surrounding the company ...

Shares of Regeneron Pharmaceuticals, Inc.REGN have dropped 35.6% in the past six months compared with the industry’s decline of 12.3%.. The stock has underperformed the sector and the S&P 500 ...